---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-300417"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:13:07.248720+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Equillium completes EQ101 Phase 2 enrollment for alopecia areata; advances EQ302 over EQ102

## Summary
- Completed enrollment of 36 patients in EQ101 Phase 2 study for alopecia areata; topline data expected Q2 2024.
- Baseline: mean SALT score of 76; 50% severe (SALT 50-94), 33% very severe (SALT >95%).
- 75% of patients had prior treatments; 11 received oral treatments including JAK inhibitors.
- EQ302 oral multi-cytokine inhibitor of IL-15 & IL-21 to be advanced for GI/skin diseases instead of EQ102.

## SEC filing metadata
- accession: 0001193125-23-300417
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/0001193125-23-300417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/d575238d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-300417
- JSON: https://secwatch.observer/filing/0001193125-23-300417.json
- Plain text: https://secwatch.observer/filing/0001193125-23-300417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.